Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2012 Jul;72(1):41-52.
doi: 10.1002/ana.23557.

Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial

Etsuro Mori  1 , Manabu Ikeda, Kenji Kosaka; Donepezil-DLB Study Investigators
Collaborators, Affiliations
Free PMC article
Randomized Controlled Trial

Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial

Etsuro Mori et al. Ann Neurol. 2012 Jul.
Free PMC article

Abstract

Objective: Because cholinergic deficits are prominent in dementia with Lewy bodies (DLB), we investigated the effects of a cholinesterase inhibitor, donepezil, in such patients in a randomized, double-blind, placebo-controlled exploratory phase 2 trial.

Methods: One-hundred forty patients with DLB, recruited from 48 specialty centers in Japan, were randomly assigned to receive placebo or 3, 5, or 10 mg of donepezil hydrochloride daily for 12 weeks (n = 35, 35, 33, and 37, respectively). Effects on cognitive function were assessed using the Mini-Mental State Examination (MMSE) and several domain-specific neuropsychological tests. Changes in behavior were evaluated using the Neuropsychiatric Inventory, caregiver burden using the Zarit Caregiver Burden Interview, and global function using the Clinician's Interview-Based Impression of Change-plus Caregiver Input (CIBIC-plus). Safety measures included the Unified Parkinson's Disease Rating Scale part III.

Results: Donepezil at 5 and 10 mg/day was significantly superior to placebo on both the MMSE (5 mg: mean difference, 3.8; 95% confidence interval [CI], 2.3-5.3; p < 0.001; 10 mg: mean difference, 2.4; 95% CI, 0.9-3.9; p = 0.001) and CIBIC-plus (p < 0.001 for each); 3 mg/day was significantly superior to placebo on CIBIC-plus (p < 0.001), but not on the MMSE (p = 0.017). Significant improvements were found also in behavioral measures (p < 0.001) at 5 and 10 mg/day and caregiver burden (p = 0.004) at 10 mg/day. The safety results were consistent with the known profile of donepezil and similar among groups.

Interpretation: Donepezil at 5 and 10mg/day produces significant cognitive, behavioral, and global improvements that last at least 12 weeks in DLB patients, reducing caregiver burden at the highest dose. Donepezil is safe and well tolerated.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Patient disposition. SAS = safety analysis set.
FIGURE 2
FIGURE 2
Mean changes from baseline in the (A) Mini-Mental State Examination and (B, C) Neuropsychiatric Inventory (B, NPI-10; C, NPI-2). Error bars represent standard deviation of the mean. LOCF = last observation carried forward.
FIGURE 3
FIGURE 3
Mean changes (95% confidence intervals) of individual Neuropsychiatric Inventory items.
See this image and copyright information in PMC

References

    1. McKeith I, Mintzer J, Aarsland D. Dementia with Lewy bodies. Lancet Neurol. 2004;3:19–28. - PubMed
    1. McKeith IG, Galasko D, Kosaka K. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. Neurology. 1996;47:1113–1124. - PubMed
    1. McKeith IG, Rowan E, Askew K. More severe functional impairment in dementia with Lewy bodies than Alzheimer disease is related to extrapyramidal motor dysfunction. Am J Geriatr Psychiatry. 2006;14:582–588. - PubMed
    1. Allan L, McKeith I, Ballard C, Kenny RA. The prevalence of autonomic symptoms in dementia and their association with physical activity, activities of daily living and quality of life. Dement Geriatr Cogn Disord. 2006;22:230–237. - PubMed
    1. McKeith IG, Dickson DW, Lowe J. Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology. 2005;65:1863–1872. - PubMed

Publication types

MeSH terms